**Core tip:** Ampulla of Vater carcinomas comprise tumors with intestinal and/or pancreaticobiliary differentiation, but such histotypical classification is of little help for their prognostic stratification. Integration of the recently reported molecular profiles with histopathological and clinical information furnishes novel keys for fostering the development of a more efficient prognostic stratification and the identification of novel therapeutic strategies.

INTRODUCTION
============

Ampullary neoplasms represent a wide array of tumors arising in the ampulla of Vater, the most common of which is represented by ampulla of Vater carcinoma (AVC), although other rare malignancies, such as neuroendocrine tumors, may be encountered in this location\[[@B1]-[@B3]\]. AVC comprises 30% of pancreatico-duodenectomies and 20% of all tumor-related obstructions of the common bile duct\[[@B4]-[@B6]\]. Data from the surveillance, epidemiology, and end results registries have indicated an increased number of new diagnoses in the last years, with the average age at diagnosis ranging from 60 to 70 years old\[[@B6]-[@B8]\]. The etiology of ampullary carcinoma has not been clearly defined and an association with a noninvasive component displaying the adenoma-to-carcinoma sequence similar to colorectal carcinoma may be present\[[@B9],[@B10]\].

The ampulla of Vater region presents very peculiar histological aspects, as it represents a crossroad of three different epithelia: Intestinal, ductal pancreatic and biliary. This kind of structure characterizes this area, with a unique complexity and morphological heterogeneity\[[@B1]\]. From the histological point of view, coupling morphological and immunohistochemical analyses, AVCs have been subgrouped into intestinal and pancreatobiliary subtypes based on the epithelium of origin; in case of coexistence of aspects of both subtypes, the mixed category has been introduced for a more precise classification\[[@B1],[@B11]-[@B14]\]. However, the former classification has been challenged by lines of evidence showing a significant interobserver variability upon the interpretation of these patterns, and the mixed subtype being the predominant subgroup of AVCs, representing up to 40% of cases\[[@B15]-[@B17]\]. In addition, poorly differentiated tumors can further confound the histological classification\[[@B1]\]. The prognostic significance of this histological classification has been subjected to investigation with inconsistent results\[[@B15]-[@B18]\] that will be briefly discussed in this review.

In recent years, much progress has been made in characterizing the molecular alterations underlying AVC tumorigenesis, showing a complex mutational spectrum that supports only in part the distinction in different histological subtypes\[[@B14],[@B17]\]. Molecular analysis showed alterations in overlapping pathways that may serve as foundation for developing new therapeutic approaches and may improve early prognostication models. In this review, we will discuss the histological and genetic landscape of AVCs and its clinical implications, with a specific focus on the treatment of choice and on the future perspectives related to this important topic.

HISTOPATHOLOGY
==============

Gross appearance and location
-----------------------------

According to the gross appearance and location, AVCs can be divided into three different categories: (1) intraampullary neoplasms, characterized by a intraluminal growth pattern, without extension out of the Oddi's sphincter; (2) periampullary neoplasms, with a significant vegetating component on the duodenal surface of the ampulla, usually adenomatous, noninvasive, and frequently characterized by an ulcerating part corresponding to the invasive component; and (3) mixed neoplasms, which show both intraampullary and vegetating growth\[[@B18]-[@B21]\]. In all of these cases, the ampullary region has a typical enlarged macroscopic appearance (Figure [1](#F1){ref-type="fig"}).

![A classic example of the macroscopic appearance of a case of ampulla of Vater carcinoma. A: The ampullary area is markedly enlarged (black arrow); B: On the section surface, the ampulla of Vater carcinoma (black box), the adjacent duodenal wall (black arrow) and bile duct (asterisk) are clearly visible.](WJGO-10-370-g001){#F1}

Histology and immunohistochemistry
----------------------------------

In 2010, the World Health Organization revised the criteria for the pathological diagnosis of ampullary carcinoma to include three distinct histopathological subtypes on the basis of morphology and immunohistochemical characteristics: (1) the intestinal-type AVCs; (2) the pancreatobiliary-type AVCs; and (3) the mixed-type AVCs\[[@B1]\].

The intestinal type is frequently associated with a noninvasive component (duodenal adenoma). Its morphology is characterized by a colorectal-like architecture, with tubular or cribriform glands and central necrosis (Figure [2](#F2){ref-type="fig"})\[[@B11],[@B22]\]. The invasive component is usually smaller than in the pancreatobiliary type and less frequently exhibits adverse pathological factors and lymphovascular and perineural invasion\[[@B23]-[@B26]\]. This AVC subtype usually expresses intestinal immunomarkers, such as caudal-related homeodomain transcription factor 2 (CDX2), mucin2 (MUC2) and cytokeratin 20 (CK20)\[[@B27]\].

![A classic example of intestinal-type ampulla of Vater carcinoma. At low magnification (2 × original magnification) and at higher magnification (the box in the upper left corner, 10 × original magnification) to better show its histological features. The lesion is composed of a colorectal-like architecture, with glands characterized by comedo-like necrosis.](WJGO-10-370-g002){#F2}

The pancreatobiliary type is morphologically similar to pancreatic ductal adenocarcinoma or to the cancer of the extra-pancreatic bile duct. Complex tubular glands composed of atypical cells and associated with a prominent desmoplastic stroma characterized this subtype (Figure [3](#F3){ref-type="fig"})\[[@B11],[@B22]\]. At immunohistochemistry, those cells stain positively for MUC1, MUC5AC and CK7\[[@B27]\].

![A classic example of pancreaticobiliary-type ampulla of Vater carcinoma (original magnification: 20 ×). The lesion is composed of ductal adenocarcinoma-like glands (black arrow) invading the duodenum (blue arrow).](WJGO-10-370-g003){#F3}

A significant proportion of AVCs, ranging between 18% and 40%, presents a hybrid phenotype characterized by overlapping intestinal and pancreatobiliary features\[[@B28],[@B29]\] and frequently by a nondistinctive immunohistochemistry (Figure [4](#F4){ref-type="fig"})\[[@B28]\]. These aspects partially explain the high interobserver variability among pathologists in classifying AVCs subtypes\[[@B15],[@B16],[@B28]\].

![Immunohistochemical analysis of an ampullary adenocarcinoma of mixed subtype (original magnification 20 ×). A: Immunohistochemical analysis of an ampullary adenocarcinoma of mixed subtype, with cytokeratin 20 (CK20); B: Immunohistochemical analysis of an ampullary adenocarcinoma of mixed subtype, with cytokeratin 7 (CK7). This image highlights that, in the same area, some neoplastic glands may be positive not only for CK7 or for CK20, but for both markers even. The coexpression of an intestinal marker, such as CK20, and of a pancreatobiliary marker, such as CK7, supports the classification as mixed subtype.](WJGO-10-370-g004){#F4}

Different immunohistochemical panels have been suggested to overcome the difficulties in histological classification, also in order to stratify AVCs prognosis (Table [1](#T1){ref-type="table"})\[[@B12],[@B13],[@B15]-[@B17]\]. A 4-marker panel including MUC1, CK20, CDX2 and MUC2 has been proposed by Ang et al\[[@B12]\]. This panel has shown improved capacities in defining intermediate/mixed cases, although its correlation with clinical outcomes has not been evaluated. Chang et al\[[@B13]\] proposed a 2-marker panel, composed of CDX2 and MUC1, showing that the PB phenotype was associated with a poor prognosis. However, more recent studies questioning the accuracy and reproducibility of this method failed in identifying direct or significant prognostic correlations with the immunohistochemical patterns\[[@B15],[@B16]\]. Notably, alterations in the "gastric" lineage marker MUC5AC have also been associated with poor outcome in AVCs, but further studies are needed to validate its prognostic role\[[@B15]\].

###### 

Proposed immunohistochemical markers for ampulla of Vater carcinoma histological classification (adapted from Mafficini et al\[[@B16]\])

  **Immunohistochemical marker criteria present**      **Intestinal type**                                                                              **Pancreatobiliary type positive**                                **Mixed/Ambiguous type**                    **Note**
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Ang et al\[[@B12]\] (MUC1, MUC2, CDX2, CK20)         Positive CK20 or CDX2 or MUC2, and negative MUC1 Positive CK20 and CDX2, and MUC2 and any MUC1   Positive MUC1 and negative CDX2, and negative MUC2 and any CK20   All other combinations                      
  Chang et al\[[@B13]\] (MUC1, CDX2)                   Positive CDX2 or negative MUC1                                                                   Negative CDX2 and positive MUC1                                   Not applicable                              CDX2 positivity based on *H* score (percentage of positive cells × intensity of staining) \> 35 MUC1 positivity based on any staining
  Gingras et al\[[@B17]\] (MUC1, CDX2)                 Ratio of the CDX2/MUC1 H score ≥ 2                                                               Ratio of the CDX2/MUC1 H score \< 0.5                             Ratio of CDX2/MUC1 H score ≥ 0.5 and \< 2   Use only MUC1 and CDX2 as per Chang et al\[[@B13]\], with H scores for both CDX2 and MUC1
  Mafficini et al\[[@B16]\] (MUC1, MUC2, CDX2, CK20)   Positive CK20 or CDX2 or MUC2, and negative MUC1                                                 Positive MUC1 and negative CDX2, and negative MUC2 and any CK20   All other combinations                      

The morphological heterogeneity that characterizes a significant proportion of AVCs and the lack of a prognostic reliability of the histological classification, either individually or within immunohistochemical panels, led to the integration of molecular alterations into clinical practice in order to better define AVCs prognosis and treatment.

GENETIC LANDSCAPE
=================

Although AVCs are usually sporadic neoplasms, they can also arise in the context of familial syndromes. Particularly, patients with familiar adenomatous polyposis (FAP) frequently develop duodenal adenomas and have a 100- to 200-fold increased risk of developing AVCs\[[@B7],[@B30],[@B31]\]. A previous seminal manuscript has indicated that sporadic AVCs differ from those occurring in FAP, according to frequency (17% *vs* 64%), as well as in the site of *APC* somatic mutations, suggesting a different molecular pathogenesis for the two conditions\[[@B32]\]. The molecular basis for AVCs initially concentrated on chromosomal alterations, indicating chromosome 5 loss as an early event in AVC carcinogenesis, and chromosome 17p loss as a poor prognostic moderator\[[@B33],[@B34]\].

Recent advances in sequencing technologies have permitted the in-depth characterization of the AVC molecular profile, providing important insights for the comprehension of the biology of this malignancy\[[@B14],[@B16],[@B17]\]. Particularly, two different whole exome sequencing analyses for a total of 240 patients have refined the knowledge about the mutational landscape of AVCs\[[@B14],[@B17]\]. Both studies confirmed the presence of recurrent alterations in well-known AVC-related genes, including *TP53*, *KRAS* and those belonging to the Wnt-pathway, such as *APC*; at the same time, *ELF3* has been indicated as a novel AVC driver gene in this kind of tumor\[[@B14]\].

The association between driver mutations and histological subtypes has been evaluated with conflicting results. The *APC* gene, an important actor of the Wnt-signaling pathway, is frequently mutated in the intestinal subtype (50%-65% of cases), similar to colorectal cancer\[[@B35]\], while the pancreatobiliary type exhibits a higher prevalence of mutations in the pancreatic driver genes *KRAS*, *TP53* and *SMAD4*, with similar frequencies to pancreatic cancer\[[@B14],[@B17],[@B36]\].

Although histological subtypes show differences in prevalence for some genes (Table [2](#T2){ref-type="table"}), important drivers, including *KRAS*, *TP53* and *ELF3*, can be found mutated in all histotypes. The lack of a specific genetic signature for the histological types suggests the existence of common biological mechanisms in the development of ampullary carcinoma, highlighting the heterogeneity of AVCs from the morphological to the molecular levels. This further calls for a reconsideration of the utility of the histological classification, since the genetic landscape indicates the lack of a specific distinction corresponding to morphology\[[@B16]\].

###### 

Frequency of significantly mutated ampulla of Vater carcinoma genes in different histotypes and compared to colorectal and pancreatic adenocarcinoma (adapted from Yachida et al\[[@B14]\])

  **Yachida et al\[[@B14]\]**   **Gingras et al\[[@B17]\]**   **Biankin et al\[[@B36]\] Pancreatic carcinoma, %**   **Colorectal Carcinoma (TCGA), %\[[@B35]\]**                                  
  ----------------------------- ----------------------------- ----------------------------------------------------- ---------------------------------------------- --------------- -------------- ---------------
  *APC* (50)                    *KRAS* (68)                   *KRAS* (50)                                           *TP53* (72)                                    *TP53* (65)     *KRAS* (99)    *APC* (81)
  *TP53* (39)                   *TP53* (67)                   *APC* (50)                                            *KRAS* (65)                                    *KRAS* (46)     *TP53* (33)    *TP53* (60)
  *KRAS* (39)                   *SMAD4* (20)                  *TP53* (41)                                           *SMAD4* (18)                                   *APC* (41)      *SMAD4* (16)   *KRAS* (43)
  *CTNNB1* (26)                 *CTNNB1* (15)                 *SMARCA4* (27)                                        *CDKN2A* (16)                                  *PIK3CA* (26)   *MLL3* (7)     *TTN* (31)
  *ARID2* (18)                  *ERBB3* (14)                  *PIK3CA* (23)                                         *PIK3CA* (13)                                  *SMAD4* (20)    *ATM* (5)      *PIK3CA* (18)
  *ERBB2* (14)                  *GNAS* (12)                   *SMAD 4* (23)                                         *ARID1A* (13)                                  *TGFBR2* (17)   *NALCN* (5)    *FBXW7* (14)
  *ACVR2A* (13)                 *CDH10* (12)                  *SOX 9* (23)                                          *APC* (11)                                     *ARID2* (17)    *ARID1A* (4)   *SMAD4* (10)
  *SMAD4* (13)                  *ELF3* (11)                   *CDKN2A* (23)                                         *ATM* (10)                                     *ELF3* (7)      *SF3B1* (4)    *NRAS* (9)
  *GNAS* (13)                   *CDKN2A* (9)                  *ARID1A* (18)                                         *TGFBR2* (10)                                  *CTNNB1* (17)   *TGFBR2* (4)   *TCF7L2* (9)
  *SOX9* (13)                                                 *TGFBR2* (14)                                         *FBXW7* (8)                                    *NF1* (15)      *ARID2* (3)    *FAM123B* (7)

Both the recent whole-exome sequencing studies described inactivating mutations in the tumor-suppressor gene *ELF3*, in respectively 10% and 12% of cases\[[@B14],[@B17]\]. In particular, Yachida et al\[[@B14]\] demonstrated with functional analyses a role of such a gene as an AVC driver. *ELF3* encodes an ETS-domain transcription factor that is implicated in the regulation of epithelial differentiation. Using immortalized epithelial cell lines derived from the common bile duct and duodenal mucosa and knocked down for *ELF3* expression, they demonstrated *ELF3* to enhance proliferation, motility and invasion, associated with the concomitant up-regulation of markers of epithelial-to-mesenchymal transition, such as vimentin, matrix metalloproteinase-1 (MMP1) and MMP9\[[@B14]\]. However, the exact functional role of *ELF3* as well as its potential role as a prognostic biomarker or target for therapy needs to be further investigated.

Interestingly, *ERBB2* amplification has been demonstrated in up 23% of cases\[[@B16],[@B37]\]. In a recent report, it was observed in 13% of AVCs regardless of histological subtype and was virtually mutually exclusive with downstream mutations in *KRAS*/*NRAS*/*BRAF*, that are responsible for resistance of therapies targeting *ERBB2*\[[@B37]\].

Molecular profiling of AVCs has recently demonstrated a higher prognostic reliability than the histological subclassification. Indeed, analyzing a cohort of 80 AVCs, Mafficini et al\[[@B16]\] showed that *TP53* and *KRAS*, which were the most frequently mutated genes, were in respectively 41% and 35% of cases, were also independent prognostic predictors of survival regardless of histological subtypes. These data underline the importance of the mixed phenotype and the fact that the ampullary region is composed of various epithelia merging to form the complex epithelium of the ampulla. Common molecular alterations among different subtypes, such as *TP53* and *KRAS*, may indeed represent drivers of tumor progression at an early stage of disease. Whereas other genetic alterations, such as those belonging to the Wnt-pathway and those characterizing the pancreatobiliary type, such as *SMAD4* and *CDKN2A*, may occur at later stages of tumor growth\[[@B14],[@B17]\].

Current treatment approaches do not distinguish patients based on subtypes\[[@B38],[@B39]\], while molecular alterations may select patients that respond to different chemotherapeutic regimens, regardless of a clear histological differentiation\[[@B17]\]. In particular, clinical testing for Wnt-signaling and microsatellite instability (MSI) could be used to subclassify tumors for target therapies since therapies targeting the Wnt-pathway are in development and MSI-positive tumors may respond to immunotherapeutic approaches\[[@B17]\]. The detection of molecular alterations typical of late-stages may in the future support the choice of radical surgery with lymphadenectomy, rather than more conservative approaches. This highlights the importance of genetic analysis and the need of its future integration within the conventional pathology report.

TUMOR STAGING
=============

The staging of AVCs is challenging due to the high complexity of this district and the three-dimensional spread pattern of tumors occurring in this region. In the new AJCC Cancer Staging System Manual, 8^th^ edition\[[@B21]\], the pathological tumor (pT) stages have been reclassified, taking into account the degree of extensions and therefore improving the clinical and prognostic relevance of each pT stage (Table [3](#T3){ref-type="table"}). In particular, new subsets for pT1, pT2 and pT3 have been introduced according to survival analyses and suggesting further prognostic variability\[[@B40]\]; the new pT4 stage comprises tumors involving peripancreatic arteries/axes, harmonizing with the exocrine pancreatic cancer staging system.

###### 

Ampulla of Vater cancer staging AJCC 2017\[[@B21]\]

  **Primary tumor (T)**          
  ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TX                             Primary tumor cannot be assessed
  T0                             No evidence of primary tumor
  Tis                            Carcinoma in situ
  T1                             Tumor limited to ampulla of Vater or sphincter of Oddi, or tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa
  T1a                            Tumor limited to ampulla of Vater or sphincter of Oddi
  T1b                            Tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa
  T2                             Tumor invades into the muscularis propria of the duodenum
  T3                             Tumor directly invades the pancreas (up to 0.5 cm) or tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery
  T3a                            Tumor directly invades pancreas, up to 0.5 cm
  T3b                            Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery
  T4                             Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size
  **Regional lymph nodes (N)**   
  **N category**                 **N criteria**
  NX                             Regional lymph nodes cannot be assessed
  N0                             No regional lymph node metastasis
  N1                             Metastasis to 1 to 3 regional lymph nodes
  N2                             Metastasis in \> 3 regional lymph nodes

Metastatic lymph nodes are present in up to 60% of surgically resected AVCs\[[@B41]-[@B43]\], with a higher rate for pancreatobiliary than intestinal type carcinomas (55% *vs* 18%)\[[@B11]\]. The new staging system categorized the presence of nodal metastases in a three-tiered scale: N0 (no metastatic lymph node), N1 (one or two metastatic lymph nodes) and N2 (three or more metastatic lymph nodes); this subclassification has demonstrated a better predictive value in stratifying the prognosis than the previous dichotomous categories N0 (no metastatic lymph node) *vs* N1 (at least one metastatic lymph node). To reach a reliable value, the gross sampling of the surgical specimen should include a minimum of 12 lymph nodes\[[@B44]\]. However, since pancreatico-duodenal nodes are the most frequently involved and are usually resected within the specimen (pancreatico-duodenectomy), even if the minimum threshold of 12 is not met, pN0 should still be assigned. Notably, a preferential lymphatic spread from pancreatico-duodenal nodes to lymph nodes around the superior mesenteric artery has been suggested, highlighting the importance of a systemic and radical lymphadenectomy in this area\[[@B45]\].

The risk for lymph node metastases according to the T stage is clinically relevant since endoscopic ampullectomy has been proposed for early AVCs. Surgical series assessed a 8%-45% risk of lymph node metastases in tumors limited to ampulla of Vater and/or sphincter of Oddi (pT1a and pT1b, respectively, of the new staging system)\[[@B42],[@B46]-[@B48]\]. The role of local excisions in surgically fit patients remains, being therefore controversial due to the relevant risk of lymph node metastases also in resected early cancers. Another pT-related issue regards the extra-nodal extension of nodal metastases, a histological feature indicating that the metastatic cells have reached the perinodal adipose tissue. In the new staging system, it has been not taken into account, whereas it has been demonstrated as an important prognostic factor in patients with AVC and other solid malignancies\[[@B49]-[@B57]\].

Other prognostic factors not included in the staging system but with a potential prognostic role are included among the histologic grading and the perineural invasion.

CLINICAL ASPECTS
================

In the majority of cases, AVCs are present with obstructive jaundice, resulting in a high resectability rate at diagnosis\[[@B4],[@B58],[@B59]\]. Other symptoms, although less common, are upper gastrointestinal bleeding, pancreatitis and unspecific abdominal pain\[[@B60]-[@B62]\]. Ampullary tumors can even be incidentally discovered during endoscopic procedures or at cross-sectional imaging performed for other reasons. Despite the potentially high resectability rate, only up to 40% of patients undergo surgical resection\[[@B6]\], mostly due to the advanced age of presentation and the significant morbidity and mortality associated with pancreatic surgery.

The diagnostic work-up usually involves abdominal imaging using ultrasonography, computed tomography and/or magnetic resonance, aiming at excluding other causes of jaundice and at disease staging. Because of the anatomical location and the frequent small size of the tumor, an ampullary mass is often difficult to detect, but indirect signs such as pancreatic and/or bile duct obstruction/dilation can be observed\[[@B62],[@B63]\].

Endoscopy plays a major role in the differential diagnosis of an altered papilla (either bulging or ulcerated) as well as in the local staging of the disease. Endoscopic biopsies are characterized by high false negative rates for adenocarcinoma, often underestimating the actual pathology\[[@B47],[@B64]\], whereas endoscopic ultrasonography (EUS) guided-biopsies improve the diagnostic accuracy, assessing the correct pathology in almost 90% of the cases\[[@B65]\]. In the local staging of ampullary masses, EUS plays a primary role thanks to its capacities of estimating the depth of tumor infiltration within the duodenal wall and in predicting the presence of local node metastases\[[@B66]-[@B68]\], although their definitive demonstration is reserved for the histological examination.

ENDOSCOPIC *VS* SURGICAL TREATMENT
==================================

Radical resection represents, to date, the only established curative option for AVCs, while an endoscopic papillectomy is indicated for noninvasive tumors. A radical resection with an adequate lymphoadenectomy is usually recommended for invasive tumors, even if very small, due to the nonnegligible risk of lymph node metastasization or of incomplete tumor resection. The correct local staging is essential to guide further treatment decisions.

Endoscopic papillectomy
-----------------------

Endoscopic papillectomy is the treatment of choice for benign or noninvasive ampullary lesions. When EUS shows a lesion confined within the mucosa, and there are not histological features of invasion or of high-grade dysplasia upon biopsy, endoscopic ampullectomy should be performed\[[@B69],[@B70]\]. The following histological examination of the endoscopic specimen must report the status of the resection margins and consider the potential presence of an invasive component\[[@B66],[@B71],[@B72]\]. In the case of high-grade dysplasia determined by endoscopic biopsy, an underlying adenocarcinoma on definitive pathology is present in 50%--100% of patients and usually in the context of voluminous intestinal-like villous adenomas, usually larger than tubular adenomas, and for which a radical endoscopic ampullectomy may be difficult\[[@B66],[@B73]\].

However, endoscopic ampullectomy should be considered part of the diagnostic process and potentially curative in cases of high-grade dysplasia and clear resection margins at the final pathological evaluation of the specimen. Considering the significant morbidity and mortality associated with pancreatic surgery, endoscopic papillectomy has also been suggested for early ampullary carcinoma, in particular for pT1 tumors\[[@B46],[@B48],[@B68]\]. However, to date, this indication remains to date controversial, mainly due to the clinically relevant risk of lymph node metastases and the high rate of positive resection margins, reserving this procedure for patients unfit for surgical resection\[[@B74]\]. Endoscopic ampullectomy is a safe procedure, characterized by a relatively low rate (about 10%) of postprocedural complications, the most common being acute pancreatitis, followed by papillary stenosis, cholangitis and bleeding\[[@B75]-[@B78]\]. Most of these complications can be prevented by the placement of temporary pancreatic and biliary stents\[[@B77],[@B79],[@B80]\].

Surgery
-------

Surgical ampullectomy has been proposed as an alternative to pancreaticoduodenectomy for selected patients with ampullary neoplasms\[[@B81]\]. This procedure is characterized by lower morbidity and mortality than major surgery, also allowing for performance of a partial lymphadenectomy (excluding the lymph nodes from the superior mesentery artery). However, its role in the treatment of AVCs is controversial, for the difficulties to obtain a radical resection\[[@B47],[@B71],[@B82]\]. Surgical ampullectomy shares the same complications of the endoscopic ampullectomy, with the risk of duodenal dehiscence and intra-abdominal collections as well as additional complications\[[@B71],[@B83]\].

The current acceptable standard of care for resectable AVCs remains the pancreatico-duodenectomy, either with conventional or pylorus-preserving approach\[[@B42],[@B46],[@B47],[@B84]\]. Surgery for AVCs is characterized by a high resectability rate, with close to 90% of cases undergoing laparotomy\[[@B7],[@B24],[@B85]\], but also by a higher rate of significant complications than pancreato-duodenectomies performed for pancreatic cancer. Such complications include pancreatic fistula, pneumonia, intra-abdominal infection, anastomotic leak, and delayed gastric emptying\[[@B86]\].

FUTURE PERSPECTIVES
===================

The histological subtypes have revealed major issues on both interobserver reproducibility and its prognostic reliability. Since the ampulla of Vater is the crossroad of three distinct epithelia, the study of the tumors arising in such a location represents a unique opportunity to better refine the knowledge about all periampullary cancers. The anatomical features of the ampulla of Vater may explain the histological heterogeneity of AVCs and the importance of also taking into account the mixed entity. Indeed, a significant part of this tumor type does not meet all the criteria for a definitive subclassification as intestinal or pancreaticobiliary-type. On the basis of such considerations, the integration of the molecular data appears as a fundamental step in understanding AVCs' biology, helping in better stratifying the prognosis, and highlighting potential targets for tailored therapy. Future therapeutic research studies should investigate, more in-depth, the AVCs histological and molecular features, which may represent the key to resolving intestinal-pancreaticobiliary heterogeneity.
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